News

Roche's phase III IMmotion151 study of Tecentriq & Avastin to treat advanced/metastatic RCC meets co-primary endpoint

NRG Therapeutics doses its first-in-human phase 1 trial for NRG5051 to treat ALS/MND and Parkinson’s disease

Stevenage, United Kingdom

Saturday, January 10, 2026, 14:00 Hrs [IST]

NRG Therapeutics Ltd, a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, announced that the first participants have

To access the full article, please log in or subscribe.

Pharma Services

Tenders & Projects

Tenders & Enquires Pharma Projects

Corporate

Company Profile Corporate Results Corporate X-ray Pharmabiz Studies of Top Companies

US FDA Update

US FDA: ANDA US FDA: Warnings US FDA: Approved NMEs US FDA: Approved NMEs US FDA: REFUSAL

Export & Import

Drug Export Procedures Drug Units With WHO GMP Certification Pharma Export Data Import Reg. Update

Pharma Laws & Documents

Notifications Pharma Regulations Patent Laws and Amendments Patent Scan Documents New Drug Approvals Notified Prices

Labs & Govt Bodies

Govt Recognised In-House R&D Units AICTE Boards & Committees List of Indian CROs List of CROs (International) Govt & approved labs of India List of State Drugs Controllers